Debt-to-equity of INFINITY PHARMACEUTICALS, INC. from 31 Mar 2012 to 30 Jun 2023
- Taxonomy & unit
- ratio: x
- Description
- Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's debt by its shareholder equity.
- Summary
-
INFINITY PHARMACEUTICALS, INC. quarterly Debt-to-equity in x history and change rate from 31 Mar 2012 to 30 Jun 2023.
- INFINITY PHARMACEUTICALS, INC. Debt-to-equity for the quarter ending 30 Jun 2023 was -2.52x, a 163% decline year-over-year.
Debt-to-equity, Quarterly (x)
Debt-to-equity, YoY Quarterly Change (%)
INFINITY PHARMACEUTICALS, INC. Quarterly Debt-to-equity (x)
| Period | Value | YoY Chg | Change % | Date |
|---|---|---|---|---|
| Q2 2023 | -2.52x | -6.53x | -163% | 30 Jun 2023 |
| Q1 2023 | -4.13x | -6.5x | -274% | 31 Mar 2023 |
| Q4 2022 | -11.84x | -13.52x | -806% | 31 Dec 2022 |
| Q3 2022 | 12.84x | +10.44x | +436% | 30 Sep 2022 |
| Q2 2022 | 4.01x | -0.32x | -7.4% | 30 Jun 2022 |
| Q1 2022 | 2.37x | -66.38x | -97% | 31 Mar 2022 |
| Q4 2021 | 1.68x | +6.46x | 31 Dec 2021 | |
| Q3 2021 | 2.4x | +13.46x | 30 Sep 2021 | |
| Q2 2021 | 4.34x | -11.5x | -73% | 30 Jun 2021 |
| Q1 2021 | 68.75x | +65.4x | +1950% | 31 Mar 2021 |
| Q4 2020 | -4.78x | -6.42x | -392% | 31 Dec 2020 |
| Q3 2020 | -11.07x | -11.94x | -1366% | 30 Sep 2020 |
| Q2 2020 | 15.83x | +15.35x | +3156% | 30 Jun 2020 |
| Q1 2020 | 3.35x | +3.08x | +1104% | 31 Mar 2020 |
| Q4 2019 | 1.64x | +1.52x | +1275% | 31 Dec 2019 |
| Q3 2019 | 0.87x | +0.73x | +519% | 30 Sep 2019 |
| Q2 2019 | 0.49x | +0.32x | +185% | 30 Jun 2019 |
| Q1 2019 | 0.28x | -0.01x | -3% | 31 Mar 2019 |
| Q4 2018 | 0.12x | -0.24x | -67% | 31 Dec 2018 |
| Q3 2018 | 0.14x | -0.29x | -67% | 30 Sep 2018 |
| Q2 2018 | 0.17x | -0.32x | -65% | 30 Jun 2018 |
| Q1 2018 | 0.29x | -0.22x | -43% | 31 Mar 2018 |
| Q4 2017 | 0.36x | -0.57x | -61% | 31 Dec 2017 |
| Q3 2017 | 0.43x | -0.85x | -66% | 30 Sep 2017 |
| Q2 2017 | 0.49x | -1.06x | -68% | 30 Jun 2017 |
| Q1 2017 | 0.51x | -1.39x | -73% | 31 Mar 2017 |
| Q4 2016 | 0.93x | -0.63x | -40% | 31 Dec 2016 |
| Q3 2016 | 1.28x | +0.08x | +6.9% | 30 Sep 2016 |
| Q2 2016 | 1.54x | +0.62x | +68% | 30 Jun 2016 |
| Q1 2016 | 1.9x | +1.22x | +179% | 31 Mar 2016 |
| Q4 2015 | 1.57x | +1.09x | +229% | 31 Dec 2015 |
| Q3 2015 | 1.2x | +0.89x | +287% | 30 Sep 2015 |
| Q2 2015 | 0.92x | +0.77x | +502% | 30 Jun 2015 |
| Q1 2015 | 0.68x | +0.55x | +412% | 31 Mar 2015 |
| Q4 2014 | 0.48x | +0.36x | +317% | 31 Dec 2014 |
| Q3 2014 | 0.31x | +0.21x | +212% | 30 Sep 2014 |
| Q2 2014 | 0.15x | +0.06x | +66% | 30 Jun 2014 |
| Q1 2014 | 0.13x | -0.11x | -44% | 31 Mar 2014 |
| Q4 2013 | 0.11x | -0.43x | -79% | 31 Dec 2013 |
| Q3 2013 | 0.1x | -1.67x | -94% | 30 Sep 2013 |
| Q2 2013 | 0.09x | -8.47x | -99% | 30 Jun 2013 |
| Q1 2013 | 0.24x | -3.74x | -94% | 31 Mar 2013 |
| Q4 2012 | 0.54x | 31 Dec 2012 | ||
| Q3 2012 | 1.77x | 30 Sep 2012 | ||
| Q2 2012 | 8.56x | 30 Jun 2012 | ||
| Q1 2012 | 3.97x | 31 Mar 2012 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.